HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

This marks the first US approval for AstraZeneca and Daiichi Sankyo's Trop-2-directed antibody drug conjugate.

Although Pfizer is not among the drugmakers suing the government to block negotiations, it has said the program will hinder drug R&D and innovation.

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

The firm will pay $45 million upfront for several new targeted agents that it plans to pair with isotopes to develop both ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The firms will combine Caris' multimodal genomic data with Ontada's community oncology-based real-world data to support cancer drug development.

On the third day, drugmakers provided updates on precision medicines for cancer and Alzheimer's, and Grail talked about the launch of a new version of the Galleri test.

The firm will use the proceeds to advance BE-101 for hemophilia B through clinical proof-of-concept testing and BE-102 for hypophosphatasia into the clinic.

The firm will use the proceeds to advance preclinical studies of its small interfering RNA therapy in KRAS-mutant colorectal and pancreatic cancer.

The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense competition among Boston hospitals.

The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.